• Home
  • About
    • Firm Profile
    • Our Team
    • Investment Process
    • How to Invest
  • Strategies
    • Loss Averse Strategies
      • Value Leaders LCV
      • Dynamic Core
      • Tactical Total Return
      • Loss Averse Equity Income
      • US Corporate Flexible Bond
      • Tactical Core
      • Emerging Healthcare
  • Commentary
    • Market In a Minute & Monthly Updates
    • PVG Market Outlook Update
    • PVG Conference Calls
    • Market in a Minute
  • Wealth Management
  • Contact
    • Client Access

Emerging Healthcare

Home Emerging Healthcare
  • Summary
  • Performance & literature

Investment Objective

PVG’s Emerging Healthcare Strategy seeks to outperform the Nasdaq Biotech Index (NBI). Over the long-term, it is expected that the strategy will significantly outperform the S&P 500. The primary focus of the strategy is investing in emerging companies that may not have revenues and may be funding clinical trials in anticipation of the development of a new drug or device.

Investment Approach

The primary focus is on emerging biotechnology, pharmaceutical, medical devices, and other innovative technologies and services. The strategy will use individual stock of smaller emerging companies but may also invest in larger companies opportunistically. The strategy may also use ETFs as well.

Risk Management

To manage risk in the strategy cash can be a significant percentage of the portfolio if opportunities do not exist or as individual positions are being changed. Inverse ETFs may be used during uncertain market conditions or to protect significant gains.

Emerging Healthcare Q3 2020
+ Summary

Investment Objective

PVG’s Emerging Healthcare Strategy seeks to outperform the Nasdaq Biotech Index (NBI). Over the long-term, it is expected that the strategy will significantly outperform the S&P 500. The primary focus of the strategy is investing in emerging companies that may not have revenues and may be funding clinical trials in anticipation of the development of a new drug or device.

Investment Approach

The primary focus is on emerging biotechnology, pharmaceutical, medical devices, and other innovative technologies and services. The strategy will use individual stock of smaller emerging companies but may also invest in larger companies opportunistically. The strategy may also use ETFs as well.

Risk Management

To manage risk in the strategy cash can be a significant percentage of the portfolio if opportunities do not exist or as individual positions are being changed. Inverse ETFs may be used during uncertain market conditions or to protect significant gains.

+ Performance & literature
Emerging Healthcare Q3 2020

Learn More About Us

  • Firm Profile
  • Our Team
  • Investment Process
  • Investment Strategies
  • How to Invest

Contact Us

6898 S. University Blvd. Suite 100
Centennial, CO 80122
Phone: (303) 526-0548
Email: information@pvgasset.com

Loss Averse Investing Strategies

  • Loss Averse Strategies
    • Value Leaders LCV
    • Dynamic Core
    • Tactical Total Return
    • Loss Averse Equity Income
    • US Corporate Flexible Bond
  • Mutual Fund

Also See

  • SEC ADV Part II
  • Form CRS
  • Manager Commentary
  • Market in a Minute Newsletter
  • Featured News & Insight
Copyright © 2019 PVG Asset Management Corporation